Comparison of Effectiveness and Safety Among 3 Direct Oral Anticoagulants in Patients With Venous Thromboembolism　― A Single-Center Retrospective Study ―

Figures

• 

  Figure 1.. Study flow chart. This study recruited 793 patients with venous thromboembolism (VTE) who were treated with oral anticoagulants; 91 patients who treated with warfarin alone were excluded, leaving 702 patients who were treated with a direct oral anticoagulant (DOAC), namely edoxaban (n=496), apixaban (n=107), and 99 rivaroxaban (n=99). Changes in thrombus volume were evaluated in 340, 86, and 78 patients treated with edoxaban, apixaban, and rivaroxaban, respectively.

• 

  Figure 2.. Cumulative incidence of (A) recurrent venous thromboembolism, (B) major bleeding, and (C) all-cause mortality in patients treated with edoxaban, apixaban, and rivaroxaban. The panels below each graph show the number of at-risk patients. DOACs, direct oral anticoagulants.

• 

  Figure 3.. Changes in thrombosis in patients treated with edoxaban, apixaban, and rivaroxaban. Changes in thrombosis were defined as follows: normalized, no thrombus in the legs and lungs; improved, improvements in both the legs and lungs or improvement in either the legs or lungs without deterioration at the other site; unchanged, no changes in both legs and lungs; and deteriorated, any deterioration in either legs or lungs.